Wed Jan 29, 2020 13:57
English | 繁體 | 简体
Click here to toggle text size
SINO BIOPHARM: Baixinuo gets approval for drug registration
11 Dec 2019
(Infocast News) Sino Biopharmaceutical (01177) announced that the “Ademetionine 1,4-Butanedisulfonate for Injection” (brand name “Baixinuo” ), a cholagogue developed by Chia-Tai Tianqing Pharmaceutical Group, a subsidiary of the company, has obtained the approval for drug registration granted by the National Medical Products Administration of the PRC. This product is applicable to the prevention of intrahepatic cholestasis before and during cirrhosis and intrahepatic cholestasis during pregnancy.

© Copyright Quamnet. All rights reserved. Republish the contents in whole or in part other than the authorized methods below, Quamnet reserves the right to proceed legal action.
Market Update
A founding member of:
China Tonghai IR:
Sitemap  |  About Us  |  Contact Us  |  Disclaimers     English | 繁體 | 简体  
Tonghai Financial:
China Tonghai International Financial Limited  |  China Tonghai Capital  |  China Tonghai Securities
Oceanwide Financial Management   |  Quamnet
Information of TonghaiIR (Investor Relations):
[Hong Kong Listed Company Information] [Financial News] [Announcement Alerts] [Free Delayed Stock Quote] [Chart]
[Hong Kong stock information]

TonghaiIR (Investor Relations) Services:
[Listed Companies Information] [Listed Companies Financial Information] [Listed Companies Announcements]
[Listed Companies Circulars] [Listed Companies News] [Press Releases] [Listed Companies Event Calendar]
[Listed Companies Presentations] [Proxy Forms]

China Tonghai IR (Investor Relations):
[Securities Firms] [Fund Houses] [Venture Capitals] [Financial Public Relations Agencies] [Financial Printers]
Investor Relations Dictionary:
[Listed Companies Result Announcement] [Financial Report] [Interim Report] [Annual General Meeting]
[Extraordinary General Meeting] [Board Meeting] [Annual Report] [Contact Listed Companies Investor Relations]
[Company Information Sheet] [Next Day Disclosure Return] [News Release] [IPO] [Prospectus] [Stock Quote] [Trading Volume]